Skip to main content
Equibles
USAQ logo

USAQ · QHSLab, Inc. · Metrics

Track USAQ — free

Use USAQ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research USAQ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.39 At close · Oct 21
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Despite the extinguishment of much of the Company's debt, the Company's history of losses combined with the amount of its revenues, raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$4.81M
Shares
15.03M
Volume · Oct 21 304 Avg daily vol (3M) 5684

USAQ metrics

65 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.39
Market cap
$4.81M

Price action

20 metrics
Price change (1W)
-15.5%
Price change (30D)
+21.5%
Price change (3M)
+37.8%
Price change (6M)
-46.8%
Price change (YTD)
-35.9%
Price change (1Y)
+104.6%
Trailing year
Price change (5Y)
-45.6%
52-week high
$0.92
52-week low
$0.16
Change from 52-week high
-57.8%
Change from 52-week low
+137.0%
Annualized volatility
265.1%
Annualized volatility (3M)
—
Beta
0.3
RSI (14D)
53.4
Price vs SMA 50
+15.2%
Price vs SMA 200
-6.0%
Avg volume (3M)
5,684
Relative volume
0.1
Average dollar volume
$1,901

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
15.03M

Valuation

12 metrics
P / E (TTM)
13.0
Trailing earnings · reciprocal yield 7.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.6×
reciprocal yield 62.7%
P / book
3.1
reciprocal yield 32.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-8.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.8×
reciprocal yield 56.7%
EV / revenue historical average (5Y)
1.8×
reciprocal yield 55.4%
EV / EBIT historical average (3Y)
22.5×
reciprocal yield 4.4%
EV / EBIT historical average (5Y)
22.5×
reciprocal yield 4.4%
EV / EBITDA historical average (3Y)
28.8×
reciprocal yield 3.5%
EV / EBITDA historical average (5Y)
28.8×
reciprocal yield 3.5%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
67.7%
Operating margin
2.7%
Trailing 12 months
Net margin
-13.0%
Gross profit (TTM)
$2.04M
Operating profit (TTM)
$82,622
Net income (TTM)
−$390,726
Trailing 12 months
Diluted EPS (TTM)
$0.03
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.11

Growth

11 metrics
Revenue growth YoY
+40.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.02M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+104.6%
Year over year · more shares
Revenue CAGR (3Y)
+29.4%
Revenue CAGR (5Y)
+84.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-25.1%
Return on assets
-20.2%
Debt / equity
—
Current ratio
1.8
EBITDA (TTM)
$154,734
Free cash flow (TTM)
—
Quick ratio
1.8
Interest coverage
0.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$317,392
Total assets
$1.93M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$463,663
Capital expenditures (TTM)
—
R&D (TTM)
$484,006
SG&A (TTM)
—
Stock compensation (TTM)
$0
R&D / revenue
16.0%
Stock compensation / revenue
0.0%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
36 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 856984 Visit website Investor relations